Aptar Pharma

http://www.aptar.com/pharma
More from Aptar Pharma
This collaboration will initially focus on bringing together connected drug delivery devices and the digital platform for asthma and chronic obstructive pulmonary disease (COPD).
Aptar and Sonmol Partner to Develop Digital Platform for Respiratory-Related Therapies
Collaboration also includes strategic investment by Aptar Pharma; will develop digital therapies and services targeting respiratory diseases.
Apr 24th, 2020
3-phase Activ-Polymer platform technology is made to offer customized active packaging systems designed to meet the drug developer’s specific formulation as well as provide a broad spectrum of drug-specific protection.
Aptar CSP Technologies: Moisture Adsorption and Oxygen Scavenging Packaging System
Oxygen scavenging and moisture adsorption system added to Aptar CSP Technologies’ 3-phase Activ-Polymer platform technology portfolio.
Feb 7th, 2020
Aptar Pharma will showcase their broad portfolio of drug delivery solutions at Pharmapack 2020
Aptar Pharma to Highlight Drug Delivery Solutions Portfolio and Expanded Services Offering at Pharmapack 2020
Jan 16th, 2020
Xcelerate optimizes the active packaging development process through end-to-end insight and expedites speed-to-market.
Aptar CSP: Xcelerate Development Services to Fast-Track Active Packaging Systems
From stability challenge to commercial launch, Xcelerate expedites the packaging process for medicines sensitive to moisture, oxygen, and volatile compounds.
Nov 27th, 2019
Stevanato Inspection
Competitive Drugs Demand Innovative Delivery Devices
Vial and syringe might be fine if you’re the only game in town. But as competition grows, so does the demand to make drug delivery easier and more convenient for patients. In many cases, your best bet is to partner for that innovation.
Oct 29th, 2019
Activ-Blister Packaging / Image: Aptar
FDA Approves Activ-Blister™ Packaging for HIV Drug
The FDA has approved AptarGroup’s packaging solution for oral solid dose HIV prevention medicine.
Oct 25th, 2019
Aptar's Nasal Unidose Device
Aptar Pharma: Nasal Unidose Device
The device has been approved for Tosymra Sumatriptan Spray by the FDA.
Oct 8th, 2019
Aptar Pharma's Unidose Powder System
Aptar’s Nasal Unidose Device Approved by US FDA for First Needle-Free Rescue Treatment for Severe Hypoglycemia
The combination product avoids time-consuming assembly for quick emergency treatment.
Aug 15th, 2019
Auto injector assembly is among the functions carried out by PCI for its global biopharmaceutical clients.
PCI Joins the Fight on Opioid Abuse
PCI addresses opioid abuse by advocating for limited medication doses and using adherence-prompting unit-dose packs. Meanwhile, it’s closely watching Amazon and e-commerce for potential impact on Rx and OTC package design.
Mar 18th, 2019